Contrary to WT p53, which is known to control stem cell populations and induce differentiation, mutated p53 can upregulate drug resistance pathways and has been correlated with stem cell transcriptional signatures in breast cancer [28, 29]. The gene discussed is TP53; the disease is breast carcinoma.